-

Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision Oncology Program To Expand Access to Genomic Testing for Veterans With Cancer

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their patients with cancer. The Veterans Health Administration is the largest integrated health system in the U.S., providing care to more than nine million Veterans annually.

The NPOP is leveraging Tempus’ broad range of comprehensive molecular profiling capabilities in an effort to improve patient outcomes with precision medicine. As part of the collaboration, providers across the VA’s 171 Medical Centers can leverage Tempus’ next-generation sequencing tests, including its solid tumor/normal assay and liquid biopsy assay. In the event of insufficient tumor tissue, Tempus offers a conversion option to a blood-based liquid biopsy test which seamlessly delivers genomic results without a delay to the clinician or the patient.

“Our AI-enabled tests combine high-quality and comprehensive genomic data with clinical data for each patient being sequenced, which allows physicians to make truly personalized decisions as they seek the optimal therapy for their patients,” said Eric Lefkofsky, Founder and CEO of Tempus. “We look forward to supporting the VA as they expand access to precision medicine solutions in oncology care to those who have served our country and deserve the very best care we have to offer.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.

Contacts

Erin Carron
Sr. Director of Communications
erin.carron@tempus.com

Tempus


Release Versions

Contacts

Erin Carron
Sr. Director of Communications
erin.carron@tempus.com

More News From Tempus

Tempus to Host Inaugural Investor Day on May 29, 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus’ leadership team, including, Founder and CEO Eric Lefkofsky, Chief Financial Officer Jim Rogers, CEO of Data and Applications Ryan Fukushima, CEO of Diagnostics Tom Schoenherr, and Chief Scientific Offic...

Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation....

Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to transform care delivery across more than 1.5 million annual patient visits to the USC Norris Comprehensive Cancer Center, t...
Back to Newsroom